Start-Ups, With An Eye On Success In Wet AMD, Tackle The Dry Form
Executive Summary
“Early and primitive” is a term frequently used to describe drug development for dry AMD in discussions with experts. Several companies have brought products to Phase II trials, but none has met the efficacy endpoints. A new crop of start-ups is trying, driven by the huge unmet demand and emerging science.
You may also be interested in...
Shire Course Corrects Lifitegrast And Eyes Ophthalmology Prospects
The specialty pharma has worked with regulators to determine a next step for its late-stage eye drug and intends to build a business unit around the compound.
Financings Of The Fortnight: Recent IPO Slowdown Not Necessarily A Harbinger For A Bad 2014
Series A financing volume is up in recent years, suggesting that 2014 will be a strong year for biotechs opting to go public. Plus financing news from Atara Biotherapeutics, Crescendo Biologics, Acucela and TetraLogic.
Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?
Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.